Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.
Molecular imaging. 0000 Jan [Epub]
Kambiz Rahbar, Ali Afshar-Oromieh, Hossein Jadvar, Hojjat Ahmadzadehfar
1 Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany., 2 Department of Nuclear Medicine, Bern University Hospital, Switzerland., 3 Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., 4 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.